Cargando…

Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been an unprecedented public health disaster in human history, and its spike (S) protein is the major target for vaccines and antiviral drug development. Although widespread vaccination has been well established, the viral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Wangqi, Jiang, Peipei, Li, Qingfeng, Wen, He, Zheng, Maolin, Zhang, Jing, Guo, Yanru, Yang, Jia, Feng, Weixu, Ye, Sisi, Kamara, Saidu, Jiang, Pengfei, Chen, Jun, Li, Wenshu, Zhu, Shanli, Zhang, Lifang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927262/ https://www.ncbi.nlm.nih.gov/pubmed/36511681 http://dx.doi.org/10.1128/spectrum.03562-22

Ejemplares similares

Novel Affibody Molecules Targeting the HPV16 E6 Oncoprotein Inhibited the Proliferation of Cervical Cancer Cells
por: Zhu, Jinshun, et al.
Publicado: (2021)

Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma
por: Kamara, Saidu, et al.
Publicado: (2023)

EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models
por: Guo, Yanru, et al.
Publicado: (2023)

Generation of affibody molecules specific for HPV16 E7 recognition
por: Xue, Xiangyang, et al.
Publicado: (2016)

Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells
por: Zhu, Jinshun, et al.
Publicado: (2020)

Correction: Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells
por: Zhu, Jinshun, et al.
Publicado: (2020)

Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma
por: Zhu, Shanli, et al.
Publicado: (2020)

Generation of a novel affibody molecule targeting Chlamydia trachomatis MOMP
por: Li, Mingyang, et al.
Publicado: (2021)

Hepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection
por: Jiang, Pengfei, et al.
Publicado: (2015)

Delta-Omicron recombinant escapes therapeutic antibody neutralization
por: Duerr, Ralf, et al.
Publicado: (2023)

Structures of Omicron spike complexes and implications for neutralizing antibody development
por: Guo, Hangtian, et al.
Publicado: (2022)

Nucleocapsid protein of SARS‐CoV‐2 is a potential target for developing new generation of vaccine
por: Feng, Weixu, et al.
Publicado: (2022)

Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
por: Cacciottolo, Mafalda, et al.
Publicado: (2023)

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody
por: Yin, Wanchao, et al.
Publicado: (2022)

SARS-CoV-2 spike protein S1 subunit induces potent neutralizing responses in mice and is effective against Delta and Omicron variants
por: Mamedov, Tarlan, et al.
Publicado: (2023)

A spike protein S2 antibody efficiently neutralizes the Omicron variant
por: Hu, Jia, et al.
Publicado: (2022)

Omicron infection of vaccinated individuals enhances neutralizing immunity against the Delta variant
por: Khan, Khadija, et al.
Publicado: (2022)

Affibody-Binding Ligands
por: Barozzi, Annalisa, et al.
Publicado: (2020)

Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
por: Bowen, John E., et al.
Publicado: (2022)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
por: Li, Wanting, et al.
Publicado: (2023)

Interface-Based Design of High-Affinity Affibody Ligands for the Purification of RBD from Spike Proteins
por: Song, Siyuan, et al.
Publicado: (2023)

Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins
por: Prandi, Ingrid Guarnetti, et al.
Publicado: (2022)

Prokaryotic expression of antibodies and affibodies
por: Fernández, Luis Angel
Publicado: (2004)

A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy
por: Meng, Lu, et al.
Publicado: (2023)

The HPV16E7 Affibody as a Novel Potential Therapeutic Agent for Treating Cervical Cancer Is Likely Internalized through Dynamin and Caveolin-1 Dependent Endocytosis
por: Zhang, Qingyuan, et al.
Publicado: (2022)

Neutralization Effect of Sera against Delta and Omicron in Patients Recovering from COVID-19 and Inactivated Vaccine Recipients
por: Zhu, Yajuan, et al.
Publicado: (2023)

DNA plasmid vaccine carrying Chlamydia trachomatis (Ct) major outer membrane and human papillomavirus 16L2 proteins for anti-Ct infection
por: Wang, Ledan, et al.
Publicado: (2017)

Neutralizing antibody responses in patients hospitalized with SARS-CoV-2 Delta or Omicron infection
por: Linderman, Susanne L., et al.
Publicado: (2022)

Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity
por: Kuzmina, Alona, et al.
Publicado: (2023)

Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
por: Servellita, Venice, et al.
Publicado: (2022)

Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron’s outbreak
por: Ren, Zhenxiao, et al.
Publicado: (2022)

Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants
por: da Costa, Clauber Henrique Souza, et al.
Publicado: (2022)

Will New Variants Emerge after Delta and Omicron?
por: Yang, Zhen, et al.
Publicado: (2022)

Affibody molecules as engineered protein drugs
por: Frejd, Fredrik Y, et al.
Publicado: (2017)

Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimers
por: Cheedarla, Narayanaiah, et al.
Publicado: (2023)

Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2
por: Han, Pengcheng, et al.
Publicado: (2022)

Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection
por: Pidal, Paola, et al.
Publicado: (2022)

SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope
por: He, Ping, et al.
Publicado: (2022)

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
por: Schultz, Bárbara M., et al.
Publicado: (2022)

Delta or Omicron BA.1/2‐neutralizing antibody levels and T‐cell reactivity after triple‐vaccination or infection
por: Rose, Ruben, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q0sfb374nh23hbjui5d40enhdf